Skip to content

News & calendar

news: as of 2026-10-12
What the marks mean

Importance is a model-assigned 1–5 on published stories, not a market forecast.

Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.

An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.

Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.

Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.

A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.

Ahead

scheduled · today and tomorrow · calendar refreshed 2026-10-12

Mon · 12 Oct · today

Tue · 13 Oct

Behind

published · newest first

Wed · 26 Aug

product

20:24
Yahoo Finance

Boeing, RTX Win $766 Mil In B-52 Modernization Contracts, Northrop Tapped For Deep Space Radar

Boeing and RTX won a combined $766 million in B-52 modernization contracts, and Northrop Grumman received an award tied to a deep space radar program. The report does not break out individual dollar amounts per contractor.

Markets open original ↗

partnership

19:08
Yahoo Finance

Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?

Amgen is ending a research partnership in Crohn's disease. The supplied text does not name the counterparty or the terms.

Markets open original ↗

product

18:52
Yahoo Finance

Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA

Roche received FDA approval for companion diagnostic tests used to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma who are eligible for ZIIHERA.

Markets open original ↗

partnership

16:30
GlobeNewswire

Incora Extends Chemical Management Services Contract with Textron

Incora extended its chemical management services contract with Textron. No contract value or term appears in the supplied text.

Markets open original ↗

funding

03:15
Yahoo Finance

Siemens Energy Plans to Carve Out Transformation of Industry Unit

Siemens Energy plans to carve out its Transformation of Industry business unit. No terms or timing appear in the supplied text.

Markets open original ↗

The wire

everything that arrived · 7 days